Protection of ΔΨ, RCR, ATP efficiency and NAD(P)H level against the deleterious effect of ischemia-reperfusion by trimetazidine treatment
| Sham-operated rats | Ischemia-reperfused rats | ||||
|---|---|---|---|---|---|
| Trimetazidine | |||||
| 0 | 5 | 10 | 20 | ||
| mg/kg | |||||
| Membrane potential (mV) | −169 ± 5.30 | −129 ± 3.901-a | −149 ± 121-b | −162 ± 5.01-c | −154 ± 6.201-c |
| RCR | 3.94 ± 0.20 | 1.51 ± 0.131-a | 1.99 ± 0.22 | 3.44 ± 0.181-c | 2.87 ± 0.231-c |
| P/O | 1.20 ± 0.06 | 0.41 ± 0.101-a | 0.78 ± 0.121-b | 1.13 ± 0.051-c | 1.15 ± 0.071-c |
| NAD(P)H level (arbitrary unit) | 445 ± 25 | 198 ± 141-a | 214 ± 24 | 433 ± 311-c | 325 ± 321-c |
Trimetazidine was administered to rats for 7 days. Their livers were then subjected to 120-min ischemia followed by 30-min reperfusion. Nontreated rats were subjected to the same ischemia-reperfusion protocol. Sham-operated rats received the same surgical procedure without being subjected to ischemia-reperfusion conditions. Liver mitochondria were then isolated from the different groups, mitochondrial membrane potential was determined using rhodamine 123, the oxygen consumption was measured polarographycally and NAD(P)H level was determined fluorometrically. Values represent mean ± SEM.